Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 04/16 11:35:19 am
189.5 GBX   +0.26%
04/16Transaction in own shares
DJ
04/14Transaction in own shares
DJ
04/12Transaction in own shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arix to Present at the Proactive One2One Virtual Investor Forum

04/08/2021 | 02:01am EDT
Arix Bioscience PLC 
Arix to Present at the Proactive One2One Virtual Investor Forum 
08-Apr-2021 / 07:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience plc 
 
Arix to Present at the Proactive One2One Virtual Investor Forum 
 
LONDON, 08 April 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing 
in and building breakthrough biotech companies, announces that Naseem Amin, Executive Chairman, will present at the 
Proactive One2One Virtual Investor Forum today, Thursday, 8 April 2021 at 7:00pm BST. Arix will be one of four 
companies presenting on the evening, each having a presentation slot followed by Q&A, with the webinar taking place 
from 6.00pm. 
Investors can register to attend here: https://event.webinarjam.com/register/1024/gwwg2hxq9 
A replay of the presentation will be available after the event, on the investor relations section of the Arix website 
at https://arixbioscience.com/investor-relations/events-presentations 
[ENDS] 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
Charlotte Parry, Head of Investor Relations 
+44 (0)20 7290 1072 
charlotte@arixbioscience.com 
 
 
Optimum Strategic Communications 
Mary Clark, Supriya Mathur, Shabnam Bashir 
+44 (0)20 3922 1906 
optimum.arix@optimumcomms.com 
 
 
About Arix Bioscience plc 
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech 
companies around cutting-edge advances in life sciences. 
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate 
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth 
phase of our industry to a broader range of investors. www.arixbioscience.com 
 
 
 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 

1182031 08-Apr-2021

(END) Dow Jones Newswires

April 08, 2021 02:00 ET (06:00 GMT)

All news about ARIX BIOSCIENCE PLC
04/16Transaction in own shares
DJ
04/14Transaction in own shares
DJ
04/12Transaction in own shares
DJ
04/08Arix to Present at the Proactive One2One Virtual Investor Forum
DJ
04/07NOVARTIS  : Joins Arix Bioscience to Develop DNA Damage Response Cancer Therapie..
MT
04/07Artios announces collaboration with Novartis to create next generation DDR ca..
DJ
04/01Total Voting Rights
DJ
03/31Transaction in own shares
DJ
03/30ARIX BIOSCIENCE  : RTW Venture Fund Unit Invest In Pyxis Oncology
MT
03/30Arix leads USD152 million Series B financing for Pyxis Oncology
DJ
More news
Financials
Sales 2021 0,50 M 0,69 M 0,69 M
Net income 2021 37,7 M 52,1 M 52,1 M
Net cash 2021 175 M 242 M 242 M
P/E ratio 2021 6,56x
Yield 2021 -
Capitalization 245 M 338 M 338 M
EV / Sales 2021 139x
EV / Sales 2022 147x
Nbr of Employees 12
Free-Float 72,7%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 231,00 GBX
Last Close Price 189,50 GBX
Spread / Highest target 35,1%
Spread / Average Target 21,9%
Spread / Lowest Target -1,32%
EPS Revisions
Managers and Directors
NameTitle
Christian Schetter Managing Director
Marcus Karia Group Finance Director
Naseem Amin Executive Chairman
Graeme Smith Chief Technology Officer
Robert Lyne COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capitalization (M$)
ARIX BIOSCIENCE PLC-13.47%338
INVESTOR AB (PUBL)21.87%66 226
CK HUTCHISON HOLDINGS LIMITED17.84%31 637
AB INDUSTRIVÄRDEN (PUBL)25.16%17 370
KINNEVIK AB15.68%16 247
HAL TRUST25.98%15 063